Merck and Regenstrief Institute Establish Evidence-Based Care Collaboration

  Merck and Regenstrief Institute Establish Evidence-Based Care Collaboration

Business Wire

WHITEHOUSE, N.J., and INDIANAPOLIS -- November 08, 2012

The Regenstrief Institute and Merck, known as MSD outside the United States
and Canada, have signed a five-year agreement to collaborate on a range of
projects that will use clinical data to inform personalized delivery of health
care. The work will explore novel methods for studying diseases and
interventions for chronic conditions such as diabetes, cardiovascular disease
and osteoporosis.

Ultimately, the Regenstrief-Merckcollaboration seeks to improve the health of
patients through data analytics, health care innovation, education and
research that supports evidence-based health care.

Financial details were not disclosed.

“Regenstrief has a passion for determining how personalization of medicine can
be achieved by better understanding and using health data,” said Regenstrief
investigator and innovations officer Jon Duke, M.D., who serves as the
institute’s lead investigator for the partnership. “Regenstrief brings
rigorous science to clinical environments and has more than 40 years of
experience as an international leader in improving health care delivery
through informatics and health services research. With Merck’s depth of
expertise and its global reach, we hope to develop and test new approaches to
care, and advance successful models of health care broadly.” Dr. Duke also is
an assistant professor of medicine at the Indiana University School of

Both Regenstrief, a medical research organization closely associated with the
Indiana University School of Medicine, and Merck, a global health care leader,
are committed to generating new knowledge to improve health.

"This type of novel academic-industry collaboration can advance our
understanding of a number of critical therapeutic areas, enabling novel use of
health information technology to enhance drug development, medication safety
and the personalization of therapeutics," said Sachin H. Jain, M.D., chief
medical information and innovation officer at Merck.

Regenstrief Institute

An internationally respected informatics and health care research
organization, the Regenstrief Institute is recognized for its role in
improving quality of care, increasing efficiency of health care delivery,
preventing medical errors and enhancing patient safety. Established in 1969,
the institute is closely associated with the Indiana University School of
Medicine and the Health and Hospital Corporation of Marion County.

About Merck

Today's Merck is a global health care leader working to help the world be
well.Merck is known as MSD outside the United States and Canada.Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions.We also demonstrate our
commitment to increasing access to health care through far-reaching policies,
programs and partnerships.For more information, visit and
connect with us on Twitter, Facebook and YouTube.

Merck Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. Such statements may include, but are not limited to,
statements about the benefits of the merger between Merck and Schering-Plough,
including future financial and operating results, the combined company’s
plans, objectives, expectations and intentions and other statements that are
not historical facts. Such statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. Actual results may differ from those set forth in the
forward-looking statements.

The following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the possibility that all of
the expected synergies from the merger of Merck and Schering-Plough will not
be realized, or will not be realized within the expected time period; the
impact of pharmaceutical industry regulation and health care legislation in
the United States and internationally; Merck’s ability to accurately predict
future market conditions; dependence on the effectiveness of Merck’s patents
and other protections for innovative products; and the exposure to litigation
and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2011
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission available at the SEC’s Internet site,


Caroline Lappetito, 267-305-7639
Regenstrief Inst
Cindy Fox Aisen, 317-843-2276
Investor Relations:
Alex Kelly, 908-423-5185
Press spacebar to pause and continue. Press esc to stop.